WO2021254327A1 - Vaccin à vecteur viral de type à remplacement d'enveloppe et procédé de construction associé - Google Patents
Vaccin à vecteur viral de type à remplacement d'enveloppe et procédé de construction associé Download PDFInfo
- Publication number
- WO2021254327A1 WO2021254327A1 PCT/CN2021/100107 CN2021100107W WO2021254327A1 WO 2021254327 A1 WO2021254327 A1 WO 2021254327A1 CN 2021100107 W CN2021100107 W CN 2021100107W WO 2021254327 A1 WO2021254327 A1 WO 2021254327A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- envelope
- ecd
- coronavirus
- virus
- Prior art date
Links
- 229940023147 viral vector vaccine Drugs 0.000 title claims abstract description 15
- 238000010276 construction Methods 0.000 title description 7
- 241000711573 Coronaviridae Species 0.000 claims abstract description 52
- 241000711975 Vesicular stomatitis virus Species 0.000 claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 44
- 239000013598 vector Substances 0.000 claims abstract description 32
- 101150010882 S gene Proteins 0.000 claims abstract description 31
- 229940096437 Protein S Drugs 0.000 claims abstract description 28
- 102000029301 Protein S Human genes 0.000 claims abstract description 27
- 150000001413 amino acids Chemical class 0.000 claims abstract description 25
- 101710198474 Spike protein Proteins 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 19
- 238000012217 deletion Methods 0.000 claims abstract description 10
- 230000037430 deletion Effects 0.000 claims abstract description 10
- 230000003834 intracellular effect Effects 0.000 claims abstract description 6
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims abstract description 4
- 101150117028 GP gene Proteins 0.000 claims abstract description 3
- 241000700605 Viruses Species 0.000 claims description 82
- 210000004027 cell Anatomy 0.000 claims description 41
- 229960005486 vaccine Drugs 0.000 claims description 29
- 239000013612 plasmid Substances 0.000 claims description 24
- 229940126580 vector vaccine Drugs 0.000 claims description 20
- 235000001014 amino acid Nutrition 0.000 claims description 17
- 108060003393 Granulin Proteins 0.000 claims description 12
- 239000013603 viral vector Substances 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims description 6
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 6
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 6
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims description 6
- 108020004705 Codon Proteins 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 4
- 101710091045 Envelope protein Proteins 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 108010066124 Protein S Proteins 0.000 claims description 4
- 101710188315 Protein X Proteins 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000001890 transfection Methods 0.000 claims description 3
- 101150062031 L gene Proteins 0.000 claims description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 2
- 230000003698 anagen phase Effects 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000013492 plasmid preparation Methods 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 241001678559 COVID-19 virus Species 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 230000003053 immunization Effects 0.000 description 19
- 238000002649 immunization Methods 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 15
- 238000004806 packaging method and process Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 230000003472 neutralizing effect Effects 0.000 description 10
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 230000016379 mucosal immune response Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- 101000674278 Homo sapiens Serine-tRNA ligase, cytoplasmic Proteins 0.000 description 6
- 101000674040 Homo sapiens Serine-tRNA ligase, mitochondrial Proteins 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 208000025721 COVID-19 Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 102100040516 Serine-tRNA ligase, cytoplasmic Human genes 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000315672 SARS coronavirus Species 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241001112090 Pseudovirus Species 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 240000000220 Panda oleosa Species 0.000 description 2
- 235000016496 Panda oleosa Nutrition 0.000 description 2
- 241001591005 Siga Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- 101100545229 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ZDS2 gene Proteins 0.000 description 1
- 101100113084 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcs2 gene Proteins 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101100167209 Ustilago maydis (strain 521 / FGSC 9021) CHS8 gene Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20251—Methods of production or purification of viral material
- C12N2760/20252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a virus vector vaccine constructed by using vesicular stomatitis virus (VSV) to effectively prevent coronavirus infection, especially including SARS-CoV-2 coronavirus envelope for replacement, and a construction method thereof.
- VSV vesicular stomatitis virus
- Coronavirus is a member of the order Nidovirals, family Coronavirus, and genus Coronavirus in the virological classification.
- the genome is a single-stranded, positive-stranded RNA with a complete genome. It is between 26-32 kb in length and is currently the largest RNA virus known in its genome. Coronavirus infections are widespread in nature, and common mammals such as dogs, cats, mice, pigs, cattle and poultry are all susceptible.
- the International Commission for Classification of Virology (ICTV, 2012) divided the members of the genus Coronavirus into four groups in its ninth report: ⁇ group, ⁇ group, ⁇ group and ⁇ group.
- Human coronaviruses are mainly distributed in the ⁇ group and ⁇ group.
- HCoV-229E and HCoV-NL63 are in the ⁇ group
- HCoV-OC43 and HCoV-HKU1 are in the 2a subgroup in the ⁇ group
- MERS-CoV belongs to the 2c subgroup in the ⁇ group
- the latest SARS-CoV- 2 and SARS belong to the 2b subgroup in the ⁇ group.
- the latest research shows that the ability of the RBD segment of the S-spike protein of the virus to bind to ACE2 is 10 times that of SARS, and the transmission capacity is the strongest among the seven major human-infecting coronaviruses currently known.
- the structure of SARS-CoV-2 is similar to SARS coronavirus.
- the spike protein S protein embodied on the surface of the virus is a specific tissue structure on the virus envelope. A large number of spike proteins are formed on the surface of the virus, which can be used as the target of virus invasion. Cells and viruses and cells play an important role.
- the global outbreak of the new crown epidemic has made it urgent to develop drugs for new crown pneumonia.
- the JAMA research report in the Journal of the American Medical Association shows that some recovered patients are still carriers of the new crown virus, which has also triggered whether the new coronavirus has become a global epidemic.
- the discussion of the new coronavirus may be like influenza virus, which has been prevalent in human society for a long time, and the envelope replacement virus vector has been proved to be the most cost-effective, effective and long-lasting disease prevention and control measure. Therefore, the whole people are vaccinated with the new coronavirus package.
- Membrane replacement virus vectors are imperative, and the development and release of new coronary pneumonia envelope replacement virus vectors in a short period of time is a powerful means to prevent the spread of the epidemic.
- pathogens that currently cause severe infectious diseases such as human immunodeficiency virus (HIV), influenza virus, severe acute respiratory syndrome virus (SARS-CoV), etc., all invade through mucosal surfaces (genital tract, respiratory tract, gastrointestinal tract) And the infected body, because the body cannot induce an effective mucosal immune response to clear the mucosal infectious pathogens, the pathogens quickly spread into the blood, and then invade the whole body, causing damage to the body, especially the lung tissue.
- HCV human immunodeficiency virus
- influenza virus influenza virus
- SARS-CoV severe acute respiratory syndrome virus
- envelope replacement virus vectors such as inactivated, protein envelope replacement virus vectors, DNA envelope replacement virus vectors, subunit envelope replacement virus vectors, etc.
- conventional routes intramuscular injection, subcutaneous, etc.
- mucosal immune response it is usually necessary to inoculate the target antigen from the mucosal site, so that it can be effectively taken up and presented by APC in the mucosal tissue, further activate the mucosal immune system, and induce effective and durable Mucosal immune response.
- VSV envelope-replacement virus vector-vesicular stomatitis virus
- VSV vesicular stomatitis virus
- VSV as a viral vector uses gene editing technology
- the strength of the body's immune response will be significantly enhanced, and a stronger acquired antiviral response (T cell immune response and B cell immune response) will be induced.
- the present invention utilizes the natural advantages of the VSV virus vector to propose an envelope replacement virus vector vaccine and its construction method.
- This kind of envelope replacement virus vector vaccine is effective against humans suffering from coronaviruses, especially SARS or new crown pneumonia virus (SARS-CoV- 2) It has a better preventive or therapeutic effect.
- an envelope-replacement type virus vector vaccine which replaces the GP gene in the rhabdovirus genome with the spike protein S gene truncation of the coronavirus or the virus spike protein S gene Extracellular segment fusion ECD-CA, and the use of reverse genetic system to construct an envelope-replacement type viral vector vaccine for the prevention of coronavirus, the ECD-CA is defined as the extracellular segment ECD of the viral spike protein S gene The gene after fusion of the transmembrane and intracellular segment genes of the VSV virus envelope protein.
- the envelope replacement virus vector vaccine is selected from vesicular stomatitis virus VSV
- the VSV is selected from the Indiana strain
- the spike protein S gene is selected from SARS or SARS- For CoV-2 coronavirus
- the spike protein S gene truncation is selected from genes corresponding to C-terminal amino acid deletions, and the number of C-terminal amino acid deletions is 18 to 72.
- the spike protein S gene truncation is selected from C-terminal deletion genes, and the number of C-terminal amino acid deletions is preferably 30, and corresponds to the modified spike protein
- the amino acid sequence corresponding to S is SEQ ID NO.1.
- the envelope replacement virus vector vaccine is selected from the vesicular stomatitis virus VSV
- the VSV is selected from the Indiana strain
- the ECD-CA is selected from coronaviruses
- the ECD-CA includes the extracellular segment ECD of the coronavirus spike protein S gene
- the C-terminus of the ECD is fused with the transmembrane and intracellular segment gene CA of the envelope protein of VSV.
- the ECD-CA is cloned into the coding sequence between the M gene and the L gene in the VSV genome, and the ECD-CA amino acid sequence is SEQ ID NO. 2,
- the ECD-CA humanized codon gene sequence is SEQ ID NO.3.
- the envelope replacement type viral vector vaccine, the vesicular stomatitis virus is a virus obtained by mutating the amino acid of its matrix protein M, and the amino acid mutation site in the matrix protein M is the bright 20th position.
- One or more of amino acid, methionine at position 51, and phenylalanine at position 110 are non-synonymous mutations.
- the amino acids corresponding to the mutation of leucine at position 20, methionine at position 51, and phenylalanine at position 110 may be the same or different from the types of the mutated amino acids in the following paragraph.
- the envelope-replacement type viral vector vaccine is an attenuated vesicular stomatitis virus
- the matrix protein M of the vesicular stomatitis virus has a 3 amino acid mutation
- the matrix protein M The 20th position was changed from Leucine L to Phenylalanine F, the 51st position was changed from Methionine M to Alanine A, and the 110th position was changed from Phenylalanine F to Leucine L, so
- the amino acid sequence of the 3-point mutant matrix protein M is SEQ ID NO.4.
- a method for constructing an envelope-replacement type viral vector vaccine includes the following steps:
- Plaque purification is performed with cells stably expressing 293-ACE2, and the coronavirus envelope replacement vaccine VSV- ⁇ G-S-CN or VSV- ⁇ G-ECD-CA is obtained after western blotting identification.
- the method for constructing the coronavirus envelope replacement virus vector vaccine is the sequence SEQ ID NO. 5.
- SEQ ID NO.6 is the sequence SEQ ID NO. 5.
- the fluorescent probe primer pair that specifically amplifies the coronavirus ECD-CA gene in RT-PCR is SEQ ID NO. 7, SEQ ID NO. 8.
- the present invention uses the VSV virus packaging system for the first time, through a large number of gene optimization and construction, in vitro screening of recombinant viruses that can efficiently package the coronavirus envelope replacement type, involving specific envelope gene modification The body (S-CN and ECD-CA), the coronavirus envelope is completely wrapped in the genetic material of VSV.
- the traditional virus vector vaccine the virus antigen can be transcribed and translated after the host cell is infected
- it can be highly immunogenic.
- the antigen is presented to immune cells, shortening the response time of the host immune system, while retaining the most important antigen protein S of the coronavirus to the greatest extent.
- coronavirus candidate vaccine involved in the invention has a certain degree of replication ability (a cell line that stably expresses hACE2), can be produced on a large scale and quickly, and at the same time as a non-inactivated vaccine, it simulates the entire process of coronavirus infecting host cells to the highest degree ( VSV structural protein is not significantly toxic to host cells), which can activate the body's immune system to produce a high-strength neutralizing antibody response against COVID-19.
- the VSV envelope replacement virus vector vaccine further adopts mucosal vaccination, which will induce the body to produce a stronger specific mucosal immune response against the coronavirus, especially the new coronary pneumonia virus (SARS-CoV-2) antigen protein S.
- SARS-CoV-2 new coronary pneumonia virus
- the mucosal tissue will be activated and the pathogen will be quickly eliminated.
- the VSV virus vector also has characteristics that other tool vectors do not have.
- the VSV virus can display the complete spatial structure of the envelope protein of the target virus on the surface of the virus, and fully expose the trimeric protein S of the new coronary pneumonia virus (SARS-CoV-2) on the recombinant virus.
- SARS-CoV-2 new coronary pneumonia virus
- the envelope-replaced virus vector of this technology type is inactivated in vitro, it still has the specific immune response that can effectively activate the body and fully activate the host immune response. After the live vaccine is inoculated, there is no secondary replication ability, which further improves the safety of the vaccine.
- Figure 1A is a schematic diagram of the construction of the S-CN and ECD-CA genes of different S truncations into the rhabdovirus backbone vector
- B is the process verification diagram of molecular biological cloning
- C is the Western Blotting detection package rescue
- D is the fluorescence image of the recombinant envelope replacement vaccine packaged by S with different modifications
- Figure 2 Screened out the two envelope replacement vaccine candidates with the highest packaging efficiency titers, and adopted different vaccination methods. After 21 days, the serum IgA content (A) and the specific IgG content (B) were detected respectively;
- Figure 3 The sera after 21 days of immunization with multiple envelope replacement candidate new coronavirus vaccines were taken out, and the simulated new coronavirus pseudovirus developed based on lentivirus was used in vitro as a detection tool to compare the titers of neutralizing antibodies;
- Figure 4 is a schematic diagram of the transformation of the envelope of the rhabdovirus vector into the envelope of the coronavirus.
- the present disclosure mainly constructs different truncated (S-CN) or ECD-CA variants of the SARS-CoV-2 virus spike protein S gene into the VSV virus backbone.
- S-CN truncated truncated virus spike protein S gene
- ECD-CA envelope gene
- the disclosed four-plasmid system is co-transfected and packaged in 293T cells stably expressed by ACE2 (human origin) to further rescue the recombinant vaccine in which the coronavirus spike protein is completely displayed on the surface of the VSV virus.
- the vaccine is vaccinated through multiple channels and after immunization Successfully induced a specific antiviral humoral immune response in healthy mice.
- the reagents and consumables used in this disclosure are as follows: Q5 Hot start High-Fidelity DNA polymerase (NEB M0493L), Mlu I-HF (NEB R3198L), Xho I (NEB R0146S), T4 DNA Ligase Enzyme (NEB M0202L), E.
- the 293T-hACE2 adherent cells were cultured in a special culture environment (Thermo BB150 cell incubator) containing 5% CO2 at 37°C, and cultured in DMEM medium.
- the modified VSV virus vector is preferably derived from the Indiana strain of vesicular stomatitis virus, and the 20th, 51st and 110th positions of the matrix protein (M) in the viral genome simultaneously have amino acid mutations,
- the amino acid substitutions are as follows: the 20th position of the matrix protein M is changed from leucine L to phenylalanine F, the 51st position is changed from methionine M to alanine A, and the 110th position is changed from phenylalanine A.
- Alanine F was mutated to Leucine L.
- the humanized codon optimization of SARS gene S is more conducive to the expression of the target gene in eukaryotic cells (after the humanized codon is optimized, the expression efficiency is increased by 10 times, which is beneficial to Recombinant virus packaging). Therefore, in this example, the released SARS-CoV-2 S amino acid sequence is humanized codon optimized to increase its expression in mammalian cells.
- the S gene code The sub-optimized sequence was synthesized by Nanjing GenScript Biotechnology Co., Ltd., and further synthesized into pCDNA3.1 eukaryotic expression vector. After PCR amplification of the target gene, the target band was recovered and purified by a fragment purification kit.
- Fragment and pVSV-3M vector use restriction endonuclease MCS1 specifically Mlul, MCS2 specifically refers to Xhol, two restriction endonucleases double digestion at 37°C for 3 hours, the next step is to gel and recover the linear vector and the target fragment. Then T4 ligase was added, ligated overnight, and then transferred to competent cells.
- the bacterial liquid PCR screened positive clones, digested with restriction enzymes and sequenced to verify the plasmid construction (and named the constructed plasmids as pCore-3M-S-C19, pCore-3M-S-C30 and pCore-3M-ECD-CA), the specific implementation steps are as follows:
- Primer synthesis and primer information The primers were synthesized by Suzhou Jinweizhi Bio-Biotechnology Co., Ltd.
- the PCR primers selected for the amplification of S-C19 and the bacterial liquid PCR primers are shown in Table 1:
- PCR primers selected for the amplification of S-C30 are shown in Table 2:
- PCR primers selected for the amplification of ECD-CA are shown in Table 3:
- Obtaining the target gene Use the pCDNA3.1 plasmid carrying the target gene (New Crown S and VSV-GP) sequence as a template, and use the primers of Table 1, Table 2, and Table 3 to perform PCR amplification S-C19, S-C30, ECD -CA, where ECD-CA fused the CA fragment to the C-terminus of the ECD segment of the S gene by overlap extension PCR;
- the positive clones were selected and transferred to a 30 mL shake flask at a ratio of 1:200, and cultured overnight at 37°C and 250 rpm in a shaker;
- VSV-WT VSV- ⁇ GS-C19
- VSV- ⁇ GS-C30 VSV- ⁇ G-ECD-CA
- the cells are collected for WB to detect the antigen expression level.
- envelope replacement plasmids of different truncations of the S gene By constructing envelope replacement plasmids of different truncations of the S gene, using the four-plasmid replicable packaging system as described in Example 1, after co-transfecting host packaging cells (293T-hACE2) for 48 hours, use 293T stably expressing hACE2 Compared with the control, the packaging efficiency of cells will be increased by 100 times. The supernatant after packaging after 0.22um filter membrane is further infected with 293T-hACE2 cells, the cytopathic changes and the expression of fluorescent reporter genes are observed, and the virus titer is determined.
- the same processing method still fails to obtain effective envelope-replaced virus particles, so a conclusion can be drawn
- the C-terminal part of the amino acid of the S gene seriously affects the expression and exocrine efficiency of the protein.
- the S gene modified variant that is, the number of amino acids deleted at the C-terminal is 18-72, especially when the deletion of 30 amino acids can be Obtain an envelope-replaceable viral vector that meets the requirements, and the initial packaging titer reaches 5E6pfu/ml.
- CA transmembrane and intracellular segment
- Table 4 The efficiency of enveloped S gene variants in rescuing recombinant viral vector vaccines
- S-C18 Can be packaged Yes
- weaker Low S-C19 Can be packaged Yes
- weaker Low S-C28 Can be packaged Yes
- weaker Low S-C30 Can be packaged Yes
- strong high S-C37 Can be packaged Yes
- weaker Low S-C53 Can be packaged Yes
- weaker Low S-C72 Can be packaged Yes
- weaker Low S-C73 Unpackaged None weaker none S-C74 Unpackaged None
- weaker none ECD-CA Can be packaged Yes
- Example 3 The immune response effect of the envelope replacement vaccine based on VSV virus vector under different immunization schemes
- test serum Dilute the test serum and the negative serum in an appropriate ratio (1:100) with antibody serum diluent (1% BSA), add 100ul per well, and incubate at 37 degrees Celsius for 2 hours;
- antibody serum diluent 1% BSA
- the two envelope-replacement viruses adopt different immunization methods and strategies.
- the levels of specific IgA and IgG antibodies in the serum significantly increased to a higher level, while the expression levels of each antibody under different immunization pathways were certain.
- the nasal drip method of immunization mainly activates the mucosal immune response and produces strong IgA specific antibodies.
- the nasal drip immunization also induces a systemic antibody immune response (Figure 2A). The statistical results can be seen from the figure.
- the intravenous and intramuscular immunization methods mainly cause the body to produce an antigen-specific IgG type immune response, and cannot produce an effective mucosal immune response (Figure 2B).
- the envelope replacement type viral vector vaccine is used After the inactivation was treated in a specific way, the mouse vaccine was given by intramuscular injection, and the content of specific antibodies in the serum was detected (indirect Elisa).
- the inactivated capsule replacement candidate vaccine also produced higher specific humoral immunity
- the high temperature inactivation of the replicable vaccine vector with the envelope replacement did not destroy the induced humoral immune response of the vaccine, which proves that it is encapsulated in the VSV genetic material
- the external spike protein S (C30) still retains sufficient immunogenicity to induce the body to produce an acquired antigen-specific humoral immune response.
- the live virus vaccine is vaccinated through the nose, no matter it is These candidate vaccines all activate the local mucosal immune response, and high secretion and expression of IgA have been detected in the serum.
- the mucosal response induced by mucosal vaccination can effectively bind to the virus surface in the early stage of new coronavirus infection.
- the antigenic position of the virus prevents the virus from entering the host cell, which greatly protects the body from the infection of the coronavirus.
- the antibody was serially diluted (1:2) 10 ⁇ L/tube with Opti-MEM.
- a positive control without antibody (20 ⁇ L virus solution, final virus concentration 4E5TU/mL) and a negative control without virus (20 ⁇ L Opti- MEM);
- Pseudovirus (a simulation system for the spike protein of the lentiviral backbone to package the new crown) is also serially diluted to 8E5TU/mL;
- step 2 Take 10 ⁇ L of the diluted virus solution (8E5TU/mL) and add it to the 10 ⁇ L serially diluted antibody in step 2 (1:1 pipetting and mixing) (at this time, the final virus concentration is 4E5pfu/mL);
- the serum neutralization titer is determined according to the dilution factor of the antibody serum corresponding to the hole with the last green fluorescence.
- the administration method of different immunization routes is further adopted. After 21 days of immunization , The level of neutralizing antibodies produced by intravenous and intramuscular immunization is higher, which is consistent with the actual administration method of this vaccine product in clinical use.
- the candidate new crown vaccine is amplified and prepared in a replicable form during production, and is produced by GMP After purification, it can be irradiated and inactivated and filled to form a preparation, speeding up the application and popularization of this type of candidate vaccine.
Abstract
L'invention concerne un vaccin à vecteur viral de type à remplacement d'enveloppe. Le virus de la stomatite vésiculaire VSV est utilisé en tant que vecteur, et le gène GP dans le génome du virus VSV est remplacé par un segment tronqué d'un gène de protéine de spicule S d'un coronavirus ou d'un ECD-CA fusionné d'un segment extracellulaire et d'un segment GP-C du gène de la protéine de spicule S du coronavirus. Le segment tronqué du gène de la protéine de spicule S est choisi parmi des gènes ayant certaines délétions d'acides aminés à l'extrémité C-terminale, et l'ECD-CA est un gène formé par fusion du segment extracellulaire du gène de protéine de spicule S du coronavirus avec les gènes de segment transmembranaire et intracellulaire de la protéine d'enveloppe virale de VSV. L'invention concerne également un procédé de construction du vaccin à vecteur viral de type à remplacement d'enveloppe.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010541093.4 | 2020-06-15 | ||
CN202010541093.4A CN111603557B (zh) | 2020-06-15 | 2020-06-15 | 一种包膜替换型病毒载体疫苗及其构建方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021254327A1 true WO2021254327A1 (fr) | 2021-12-23 |
Family
ID=72195008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/100107 WO2021254327A1 (fr) | 2020-06-15 | 2021-06-15 | Vaccin à vecteur viral de type à remplacement d'enveloppe et procédé de construction associé |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN111603557B (fr) |
WO (1) | WO2021254327A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114540419A (zh) * | 2022-03-04 | 2022-05-27 | 中国人民解放军军事科学院军事医学研究院 | 一种分析包膜病毒膜融合效率的三功能报告系统 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111603557B (zh) * | 2020-06-15 | 2023-11-28 | 睿丰康生物医药科技(浙江)有限公司 | 一种包膜替换型病毒载体疫苗及其构建方法 |
CN111893097A (zh) * | 2020-06-16 | 2020-11-06 | 惠君生物医药科技(杭州)有限公司 | 一种冠状病毒假病毒包装系统及一步法包装方法 |
CN114437206B (zh) * | 2020-09-23 | 2023-05-16 | 深圳市因诺赛生物科技有限公司 | 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用 |
CN112213497B (zh) * | 2020-09-24 | 2023-10-20 | 杭州医学院 | 检测新型冠状病毒s蛋白独特性抗体的多肽-elisa试剂盒 |
CN112266411B (zh) * | 2020-09-25 | 2022-06-24 | 北京诺思兰德生物技术股份有限公司 | 一种新型冠状病毒疫苗及其应用 |
CN112226413B (zh) * | 2020-10-14 | 2022-04-15 | 苏州大学 | 基于SARS-CoV-2 S蛋白RBD区域的靶向性外泌体及其制备方法 |
CN112618707B (zh) * | 2020-10-15 | 2023-07-04 | 广州达博生物制品有限公司 | 一种SARS-CoV-2冠状病毒疫苗及其制备方法 |
CN112251413B (zh) * | 2020-10-15 | 2021-05-14 | 焦顺昌 | 一种跨膜表达新型冠状病毒抗原的细胞的制备方法、细胞和应用 |
CN113480618A (zh) * | 2020-10-16 | 2021-10-08 | 浙江大学 | 表达新冠病毒蛋白的重组麻疹病毒及其应用 |
WO2022092779A1 (fr) * | 2020-10-29 | 2022-05-05 | 에스케이바이오사이언스 주식회사 | Vecteur viral comprenant un matériau d'antigène du sras-coronavirus-2 et son utilisation |
US20240000920A1 (en) * | 2020-11-12 | 2024-01-04 | Intervet Inc. | Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof |
CN114751964B (zh) * | 2020-12-29 | 2024-03-08 | 苏州方舟生物科技有限公司 | β属冠状病毒通用疫苗蛋白片段及其筛选方法和应用 |
CN112375784B (zh) * | 2021-01-07 | 2021-04-16 | 北京百普赛斯生物科技股份有限公司 | 制备重组新型冠状病毒Spike蛋白的方法 |
CN112724209B (zh) * | 2021-01-18 | 2022-03-08 | 广东华南疫苗股份有限公司 | 可形成纳米颗粒的冠状病毒重组蛋白及其载体和应用 |
CN112940086B (zh) * | 2021-02-26 | 2022-06-03 | 深圳市亚辉龙生物科技股份有限公司 | 新型冠状病毒抗原及其应用 |
WO2022253134A1 (fr) * | 2021-05-31 | 2022-12-08 | 神州细胞工程有限公司 | Procédé pour améliorer l'immunogénicité/la stabilité de trimère antigénique d'un antigène ecd de souche mutante de sars-cov-2 |
CN115594742A (zh) * | 2021-07-09 | 2023-01-13 | 复旦大学(Cn) | 一种冠状病毒s蛋白变体及其应用 |
CN113559254B (zh) * | 2021-08-09 | 2023-02-10 | 苏州大学 | 一种狂犬病毒疫苗及其制备方法 |
CN113817753B (zh) * | 2021-09-07 | 2024-04-09 | 上海交通大学 | 表达SARS-CoV-2纤突蛋白或其变异体SΔ21的假型化VSV病毒构建和应用 |
CN114032217A (zh) * | 2021-11-02 | 2022-02-11 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于dna载体和复制型痘苗病毒载体的新冠病毒复合型疫苗 |
CN114605504B (zh) * | 2022-02-25 | 2023-05-09 | 宁波大学 | 一种可诱导植物细胞坏死的小麦黄花叶病毒14k蛋白及其在抗病毒中的用途 |
CN115820572A (zh) * | 2022-09-15 | 2023-03-21 | 军事科学院军事医学研究院军事兽医研究所 | 一种表达双拷贝拉沙热病毒gp基因的重组病毒株及其构建方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111088283A (zh) * | 2020-03-20 | 2020-05-01 | 苏州奥特铭医药科技有限公司 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
CN111603557A (zh) * | 2020-06-15 | 2020-09-01 | 苏州奥特铭医药科技有限公司 | 一种包膜替换型病毒载体疫苗及其构建方法 |
CN111893097A (zh) * | 2020-06-16 | 2020-11-06 | 惠君生物医药科技(杭州)有限公司 | 一种冠状病毒假病毒包装系统及一步法包装方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX343109B (es) * | 2004-04-09 | 2016-10-25 | Wyeth * | Atenuacion sinergistica del virus de la estomatitis vesicular, vectores de los mismos y composiciones inmunogenicas de los mismos. |
-
2020
- 2020-06-15 CN CN202010541093.4A patent/CN111603557B/zh active Active
- 2020-06-15 CN CN202311779716.1A patent/CN117752779A/zh active Pending
-
2021
- 2021-06-15 WO PCT/CN2021/100107 patent/WO2021254327A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111088283A (zh) * | 2020-03-20 | 2020-05-01 | 苏州奥特铭医药科技有限公司 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
CN111603557A (zh) * | 2020-06-15 | 2020-09-01 | 苏州奥特铭医药科技有限公司 | 一种包膜替换型病毒载体疫苗及其构建方法 |
CN111893097A (zh) * | 2020-06-16 | 2020-11-06 | 惠君生物医药科技(杭州)有限公司 | 一种冠状病毒假病毒包装系统及一步法包装方法 |
Non-Patent Citations (4)
Title |
---|
DATABASE PROTEIN 11 May 2020 (2020-05-11), ANONYMOUS : "surface glycoprotein [Severe acute respiratory syndrome coronavirus 2]", XP055881600, retrieved from NCBI Database accession no. QJR85833 * |
FENG YANGBING, SHAN YA-JUN, YUAN XIAO-LING, YANG ZHEN, ZHAO ZHEN-HU, WANG SHENG-QI, LIU XIAO-HUI, CONG YU-WEN: "Cloning of the Gene of SARS-CoV S Protein and Construction of the Fusion Expression Vector of S Protein with VSV-G", LETTERS IN BIOTECHNOLOGY, JUNSHI YIXUE KEXUEYUAN, CN, vol. 15, no. 1, 31 January 2004 (2004-01-31), CN , pages 9 - 12, XP055881592, ISSN: 1009-0002 * |
TANG XIAOYAN: "Construction of A Recombinant Chimeric Vesicular Stomatitis Virus Expressing SARS-CoV Spike Protein and Evaluation Its Immunogenicity in Mice and Rhesus Monkeys", CHINESE DOCTORAL DISSERTATIONS FULL-TEXT DATABASE (ELECTRONIC JOURNAL), no. 1, 15 January 2021 (2021-01-15), XP055881596 * |
YAHALOM-RONEN YFAT, TAMIR HADAS, MELAMED SHARON, POLITI BOAZ, SHIFMAN OHAD, ACHDOUT HAGIT, VITNER EINAT B., ISRAELI OFIR, MILROT E: "A single dose of recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challenge", NATURE COMMUNICATIONS, vol. 11, no. 1, 16 December 2020 (2020-12-16), pages 1 - 13, XP055828194, DOI: 10.1038/s41467-020-20228-7 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114540419A (zh) * | 2022-03-04 | 2022-05-27 | 中国人民解放军军事科学院军事医学研究院 | 一种分析包膜病毒膜融合效率的三功能报告系统 |
Also Published As
Publication number | Publication date |
---|---|
CN111603557A (zh) | 2020-09-01 |
CN111603557B (zh) | 2023-11-28 |
CN117752779A (zh) | 2024-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021254327A1 (fr) | Vaccin à vecteur viral de type à remplacement d'enveloppe et procédé de construction associé | |
WO2021185310A1 (fr) | Vecteur de virus mvsv, vaccin à vecteur viral associé et nouveau vaccin contre la pneumonie à coronavirus basé sur la médiation par mvsv | |
CN111821433B (zh) | mRNA疫苗及其合成方法、试剂盒 | |
Davis et al. | West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays | |
Toro et al. | Infectious bronchitis virus subpopulations in vaccinated chickens after challenge | |
TWI605124B (zh) | 新穎桿狀病毒載體及使用方法 | |
CN104962581B (zh) | 一种表达非洲猪瘟病毒p72蛋白的重组病毒疫苗株 | |
CN109536461B (zh) | 一种o型口蹄疫病毒突变株及其制备方法和应用 | |
CN111778264A (zh) | 基于新型腺病毒载体Sad23L和/或Ad49L的新型冠状病毒肺炎疫苗 | |
US11179459B1 (en) | Vaccine composition for preventing human infection of SARS coronavirus and alleviating infection symptoms | |
CN108040484A (zh) | 基于慢病毒载体的日本脑炎免疫原性组合物 | |
CN108210921A (zh) | 一种寨卡病毒疫苗及其制备方法 | |
WO2022068846A1 (fr) | Nouveau vaccin à arnm contre un coronavirus, sa méthode de préparation et son utilisation | |
Gonin et al. | Immunization trial of cats with a replication-defective adenovirus type 5 expressing the ENV gene of feline immunodeficiency virus | |
CN113817753B (zh) | 表达SARS-CoV-2纤突蛋白或其变异体SΔ21的假型化VSV病毒构建和应用 | |
JP2024512575A (ja) | 弱毒化されたレオウイルスベースのワクチン組成物及びその用途 | |
WO2021212101A1 (fr) | Compositions pour le traitement et/ou la prévention d'infections au coronavirus | |
CN113801206A (zh) | 利用受体识别域诱导抗新冠病毒中和抗体的方法 | |
Liu et al. | Rescue and characterization of a recombinant HY12 bovine enterovirus carrying a foreign HA epitope in the 3A nonstructural protein | |
Ávila-Nieto et al. | Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant | |
CN116904489B (zh) | 一种鸭坦布苏病毒核酸疫苗及应用 | |
US9181306B2 (en) | Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine | |
US11111275B2 (en) | Compositions and methods for making and using virus-like particles (VLPs) | |
WO2023202711A1 (fr) | Vaccin à arnm basé sur un nouveau coronavirus | |
WO2024055273A1 (fr) | Vaccin contre l'arnm de la rage et sa préparation et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21825737 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21825737 Country of ref document: EP Kind code of ref document: A1 |